Man Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Man Group’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-135,000	Closed	-$5.19M	–	2236
2023 Q2	$5.19M	Buy	+135,000	New	+$3.47M	0.02%	860
2019 Q2	–	Sell	-2,600	Closed	-$52K	–	2046
2019 Q1	$52K	Buy	+2,600	New	+$45.3K	﹤0.01%	1932

Man Group's KDNY Position: Q3 2023 in Review

Man Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 135,000 shares — an estimated $5.19M sold.

Man Group first reported a position in KDNY in Q1 2019 and held it in 2 quarters. The position peaked at $5.19M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Man Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Man Group sold 135,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $5.19M.
Man Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
Man Group's Chinook Therapeutics, Inc. Common Stock position peaked at $5.19M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Man Group's 13F filing for Q3 2023, filed 14 Nov 2023.